Condition: Sickle Cell Disease · Sponsor: Novartis Pharmaceuticals
A phase III, multi-center, randomized, placebo-controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult Sickle Cell Disease patients with frequent vaso-occlusive crises.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111
Always discuss trial participation with your own doctor first.
| University Of Alabama | Birmingham, Alabama, United States | Recruiting |
| Ctr for Inherited Blood Disorders | Orange, California, United States | Recruiting |
| Childrens National Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| University of Florida | Jacksonville, Florida, United States | Recruiting |
| Augusta University Georgia | Augusta, Georgia, United States | Recruiting |
| WCG Sonar Clinical Research | Riverdale, Georgia, United States | Recruiting |
| Norton Children s Hospital | Louisville, Kentucky, United States | Recruiting |
| The Johns Hopkins University School of Medicine | Baltimore, Maryland, United States | Recruiting |
| Southern Specialty Research | Flowood, Mississippi, United States | Recruiting |
| Childrens Hospital at Montefiore | The Bronx, New York, United States | Recruiting |
| East Carolina University | Greenville, North Carolina, United States | Recruiting |
| Wake Forest University Baptist Medical Center | Winston-Salem, North Carolina, United States | Recruiting |
+ 20 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06439082